KMDA

Kamada Ltd. is an Israeli biopharmaceutical company specializing in plasma-derived protein therapeutics and biopharmaceutical products. The company develops, manufactures, and markets specialty pharmaceutical products with a focus on orphan indications and niche markets. Kamada's portfolio includes treatments for rare diseases such as hereditary angioedema, alpha-1 antitrypsin deficiency, and immunodeficiency disorders. The company operates its own plasma fractionation facility and partners with healthcare organizations globally to distribute its products.